Cargando…

Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series

BACKGROUND: Following recent approval of pirfenidone and nintedanib for idiopathic pulmonary fibrosis (IPF), questions arise about the use of these antifibrotics in patients awaiting lung transplantation (LTx). METHODS: Safety and efficacy of antifibrotic drugs in IPF patients undergoing LTx were in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Delanote, Isabelle, Wuyts, Wim A., Yserbyt, Jonas, Verbeken, Eric K., Verleden, Geert M., Vos, Robin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5116160/ https://www.ncbi.nlm.nih.gov/pubmed/27863518 http://dx.doi.org/10.1186/s12890-016-0308-z

Ejemplares similares

Multiplex protein profiling of bronchoalveolar lavage in idiopathic pulmonary fibrosis and hypersensitivity pneumonitis
por: Stijn, Willems, et al.
Publicado: (2013)

Antifibrotic drugs in lung transplantation and chronic lung allograft dysfunction: a review
por: Bos, Saskia, et al.
Publicado: (2021)

Progression in the Management of Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Diseases, Where Are We Now and Where We Would Like to Be
por: Goos, Tinne, et al.
Publicado: (2021)

Effects of Corticosteroid Treatment and Antigen Avoidance in a Large Hypersensitivity Pneumonitis Cohort: A Single-Centre Cohort Study
por: De Sadeleer, Laurens J., et al.
Publicado: (2018)

ANTIFIBROTIC THERAPY IN IDIOPATHIC PULMONARY FIBROSIS
por: Scullion, T., et al.
Publicado: (2017)

Montelukast for bronchiolitis obliterans syndrome after lung transplantation: A randomized controlled trial
por: Ruttens, David, et al.
Publicado: (2018)

A role for telomere length and chromosomal damage in idiopathic pulmonary fibrosis
por: McDonough, John E., et al.
Publicado: (2018)

Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
por: Maher, Toby M., et al.
Publicado: (2019)

Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis
por: Sugino, Keishi, et al.
Publicado: (2021)

Antifibrotic therapy in idiopathic pulmonary fibrosis candidates for lung transplantation undergoing pulmonary rehabilitation
por: Pereira, Monica Pruss, et al.
Publicado: (2023)

Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis
por: Kang, Jieun, et al.
Publicado: (2021)

Does continuation of antifibrotics before lung transplantation influence post-transplant outcomes in patients with idiopathic pulmonary fibrosis?
por: Zhu, Michael Z L, et al.
Publicado: (2021)

Real-world retrospective observational study exploring the effectiveness and safety of antifibrotics in idiopathic pulmonary fibrosis
por: Wright, William Alexander, et al.
Publicado: (2021)

The MUC5B Promoter Polymorphism is Not Associated With Non-ILD Chronic Respiratory Diseases or Post-transplant Outcome
por: Goos, Tinne, et al.
Publicado: (2022)

The Role of Surgical Lung Biopsy in Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis
por: Limper, Andrew H.
Publicado: (2019)

Antifibrotic drugs for idiopathic pulmonary fibrosis: What we should know?
por: Hadda, Vijay, et al.
Publicado: (2020)

Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications
por: Kelly, Bryan T., et al.
Publicado: (2021)

Mortality and Respiratory-Related Hospitalizations in Idiopathic Pulmonary Fibrosis Not Treated With Antifibrotics
por: Cottin, Vincent, et al.
Publicado: (2021)

Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
por: Collins, Bridget F., et al.
Publicado: (2019)

Antifibrotics and Reduced Mortality in Idiopathic Pulmonary Fibrosis: Immortal Time Bias
por: Suissa, Samy, et al.
Publicado: (2022)

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
por: Richeldi, Luca, et al.
Publicado: (2020)

Effect of genotype on the disease course in idiopathic pulmonary fibrosis despite antifibrotic treatment
por: Sterclova, Martina, et al.
Publicado: (2021)

B Cells in Idiopathic Pulmonary Fibrosis: Targeting Immune Cells with Antifibrotic Agents
por: Roman, Jesse, et al.
Publicado: (2021)

Changes in serum metabolomics in idiopathic pulmonary fibrosis and effect of approved antifibrotic medication
por: Seeliger, Benjamin, et al.
Publicado: (2022)

Idiopathic pleuroparenchymatous fibroelastosis: A case report and brief review of the literature
por: Cuppens, Kristof, et al.
Publicado: (2014)

Broad Adoption of Antifibrotics in Idiopathic Pulmonary Fibrosis: Still a Long Way to Go
por: Assayag, Deborah
Publicado: (2021)

Fatigue in idiopathic pulmonary fibrosis measured by the Fatigue Assessment Scale during antifibrotic treatment
por: Kølner-Augustson, Line, et al.
Publicado: (2020)

Benefits of Pulmonary Rehabilitation in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Drug Treatment
por: Iwanami, Yuji, et al.
Publicado: (2022)

A survival analysis of idiopathic pulmonary fibrosis in the context of antifibrotic therapy in Saudi Arabia
por: Khan, Mohammed Ayaz, et al.
Publicado: (2023)

Antifibrotic therapies reduce mortality and hospitalization among Medicare beneficiaries with idiopathic pulmonary fibrosis
por: Mooney, Joshua, et al.
Publicado: (2021)

Connective Tissue Growth Factor Is Overexpressed in Explant Lung Tissue and Broncho-Alveolar Lavage in Transplant-Related Pulmonary Fibrosis
por: Vanstapel, Arno, et al.
Publicado: (2021)

Double Lung Transplantation for Idiopathic Pulmonary Fibrosis in a Patient with a History of Liver Transplantation and Prolonged Journey for Disease-Specific Antifibrotic Therapy
por: Majewski, Sebastian, et al.
Publicado: (2022)

Towards the Essence of Progressiveness: Bringing Progressive Fibrosing Interstitial Lung Disease (PF-ILD) to the Next Stage
por: De Sadeleer, Laurens J., et al.
Publicado: (2020)

Antifibrotic therapies to control cardiac fibrosis
por: Fan, Zhaobo, et al.
Publicado: (2016)

Impact of novel antifibrotic therapy on patient outcomes in idiopathic pulmonary fibrosis: patient selection and perspectives
por: Graney, Bridget A, et al.
Publicado: (2018)

Antifibrotic treatment response and prognostic predictors in patients with idiopathic pulmonary fibrosis and exposed to occupational dust
por: Casillo, Valeria, et al.
Publicado: (2019)

Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry
por: Salisbury, Margaret L., et al.
Publicado: (2020)

Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients
por: Proesmans, V. L. J., et al.
Publicado: (2019)

High-Resolution CT Change over Time in Patients with Idiopathic Pulmonary Fibrosis on Antifibrotic Treatment
por: Balestro, Elisabetta, et al.
Publicado: (2019)

Radiomics for the Prediction of Response to Antifibrotic Treatment in Patients with Idiopathic Pulmonary Fibrosis: A Pilot Study
por: Yang, Cheng-Chun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_faq6cu01utv0gkavltkts8v05i